Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement fromthe European Atherosclerosis Society Consensus Panel

Brian A. Ference, Henry N. Ginsberg, Ian Graham, Kausik K. Ray, Chris J. Packard, Eric Bruckert, Robert A. Hegele, Ronald M. Krauss, Frederick J. Raal, Heribert Schunkert, Gerald F. Watt, Jan Borén, Sergio Fazio, Jay D. Horton, Luis Masana, Stephen J. Nicholls, Børge G. Nordestgaard, Bart Van De Sluis, Marja Riitta Taskinen, Lale Tokgözoǧlu & 6 others Ulf Landmesser, Ulrich Laufs, Olov Wiklund, Jane K. Stock, M. John Chapman, Alberico L. Catapano

Research output: Contribution to journalArticle

326 Citations (Scopus)

Abstract

Aims To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD). Methods and results We assessed whether the association between LDL and ASCVD fulfils the criteria for causality by evaluating the totality of evidence from genetic studies, prospective epidemiologic cohort studies, Mendelian randomization studies, and randomized trials of LDL-lowering therapies. In clinical studies, plasma LDL burden is usually estimated by determination of plasma LDL cholesterol level (LDL-C). Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD, whereas rare variants leading to lower LDL-C are associated with a correspondingly lower risk of ASCVD. Separate meta-analyses of over 200 prospective cohort studies, Mendelian randomization studies, and randomized trials including more than 2 million participants with over 20 million person-years of follow-up and over 150 000 cardiovascular events demonstrate a remarkably consistent dose-dependent log-linear association between the absolute magnitude of exposure of the vasculature to LDL-C and the risk of ASCVD; and this effect appears to increase with increasing duration of exposure to LDL-C. Both the naturally randomized genetic studies and the randomized intervention trials consistently demonstrate that any mechanism of lowering plasma LDL particle concentration should reduce the risk of ASCVD events proportional to the absolute reduction in LDL-C and the cumulative duration of exposure to lower LDL-C, provided that the achieved reduction in LDL-C is concordant with the reduction in LDL particle number and that there are no competing deleterious off-target effects. Conclusion Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.

Original languageEnglish (US)
Pages (from-to)2459-2472
Number of pages14
JournalEuropean Heart Journal
Volume38
Issue number32
DOIs
StatePublished - Aug 21 2017

Fingerprint

LDL Lipoproteins
Epidemiologic Studies
Cardiovascular Diseases
Random Allocation
Clinical Studies
Cohort Studies
Prospective Studies
LDL Receptors
HDL Lipoproteins
Causality
LDL Cholesterol
Meta-Analysis

Keywords

  • Atherosclerosis
  • Cardiovascular disease
  • Causality
  • Clinical trials
  • Ezetimibe
  • Low-density lipoprotein
  • Mendelian randomization
  • PCSK9
  • Recommendations
  • Statin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement fromthe European Atherosclerosis Society Consensus Panel. / Ference, Brian A.; Ginsberg, Henry N.; Graham, Ian; Ray, Kausik K.; Packard, Chris J.; Bruckert, Eric; Hegele, Robert A.; Krauss, Ronald M.; Raal, Frederick J.; Schunkert, Heribert; Watt, Gerald F.; Borén, Jan; Fazio, Sergio; Horton, Jay D.; Masana, Luis; Nicholls, Stephen J.; Nordestgaard, Børge G.; Van De Sluis, Bart; Taskinen, Marja Riitta; Tokgözoǧlu, Lale; Landmesser, Ulf; Laufs, Ulrich; Wiklund, Olov; Stock, Jane K.; Chapman, M. John; Catapano, Alberico L.

In: European Heart Journal, Vol. 38, No. 32, 21.08.2017, p. 2459-2472.

Research output: Contribution to journalArticle

Ference, BA, Ginsberg, HN, Graham, I, Ray, KK, Packard, CJ, Bruckert, E, Hegele, RA, Krauss, RM, Raal, FJ, Schunkert, H, Watt, GF, Borén, J, Fazio, S, Horton, JD, Masana, L, Nicholls, SJ, Nordestgaard, BG, Van De Sluis, B, Taskinen, MR, Tokgözoǧlu, L, Landmesser, U, Laufs, U, Wiklund, O, Stock, JK, Chapman, MJ & Catapano, AL 2017, 'Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement fromthe European Atherosclerosis Society Consensus Panel', European Heart Journal, vol. 38, no. 32, pp. 2459-2472. https://doi.org/10.1093/eurheartj/ehx144
Ference, Brian A. ; Ginsberg, Henry N. ; Graham, Ian ; Ray, Kausik K. ; Packard, Chris J. ; Bruckert, Eric ; Hegele, Robert A. ; Krauss, Ronald M. ; Raal, Frederick J. ; Schunkert, Heribert ; Watt, Gerald F. ; Borén, Jan ; Fazio, Sergio ; Horton, Jay D. ; Masana, Luis ; Nicholls, Stephen J. ; Nordestgaard, Børge G. ; Van De Sluis, Bart ; Taskinen, Marja Riitta ; Tokgözoǧlu, Lale ; Landmesser, Ulf ; Laufs, Ulrich ; Wiklund, Olov ; Stock, Jane K. ; Chapman, M. John ; Catapano, Alberico L. / Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement fromthe European Atherosclerosis Society Consensus Panel. In: European Heart Journal. 2017 ; Vol. 38, No. 32. pp. 2459-2472.
@article{0ff42ce0da5c4a99b839543062cefa46,
title = "Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement fromthe European Atherosclerosis Society Consensus Panel",
abstract = "Aims To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD). Methods and results We assessed whether the association between LDL and ASCVD fulfils the criteria for causality by evaluating the totality of evidence from genetic studies, prospective epidemiologic cohort studies, Mendelian randomization studies, and randomized trials of LDL-lowering therapies. In clinical studies, plasma LDL burden is usually estimated by determination of plasma LDL cholesterol level (LDL-C). Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD, whereas rare variants leading to lower LDL-C are associated with a correspondingly lower risk of ASCVD. Separate meta-analyses of over 200 prospective cohort studies, Mendelian randomization studies, and randomized trials including more than 2 million participants with over 20 million person-years of follow-up and over 150 000 cardiovascular events demonstrate a remarkably consistent dose-dependent log-linear association between the absolute magnitude of exposure of the vasculature to LDL-C and the risk of ASCVD; and this effect appears to increase with increasing duration of exposure to LDL-C. Both the naturally randomized genetic studies and the randomized intervention trials consistently demonstrate that any mechanism of lowering plasma LDL particle concentration should reduce the risk of ASCVD events proportional to the absolute reduction in LDL-C and the cumulative duration of exposure to lower LDL-C, provided that the achieved reduction in LDL-C is concordant with the reduction in LDL particle number and that there are no competing deleterious off-target effects. Conclusion Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.",
keywords = "Atherosclerosis, Cardiovascular disease, Causality, Clinical trials, Ezetimibe, Low-density lipoprotein, Mendelian randomization, PCSK9, Recommendations, Statin",
author = "Ference, {Brian A.} and Ginsberg, {Henry N.} and Ian Graham and Ray, {Kausik K.} and Packard, {Chris J.} and Eric Bruckert and Hegele, {Robert A.} and Krauss, {Ronald M.} and Raal, {Frederick J.} and Heribert Schunkert and Watt, {Gerald F.} and Jan Bor{\'e}n and Sergio Fazio and Horton, {Jay D.} and Luis Masana and Nicholls, {Stephen J.} and Nordestgaard, {B{\o}rge G.} and {Van De Sluis}, Bart and Taskinen, {Marja Riitta} and Lale Tokg{\"o}zoǧlu and Ulf Landmesser and Ulrich Laufs and Olov Wiklund and Stock, {Jane K.} and Chapman, {M. John} and Catapano, {Alberico L.}",
year = "2017",
month = "8",
day = "21",
doi = "10.1093/eurheartj/ehx144",
language = "English (US)",
volume = "38",
pages = "2459--2472",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "32",

}

TY - JOUR

T1 - Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement fromthe European Atherosclerosis Society Consensus Panel

AU - Ference, Brian A.

AU - Ginsberg, Henry N.

AU - Graham, Ian

AU - Ray, Kausik K.

AU - Packard, Chris J.

AU - Bruckert, Eric

AU - Hegele, Robert A.

AU - Krauss, Ronald M.

AU - Raal, Frederick J.

AU - Schunkert, Heribert

AU - Watt, Gerald F.

AU - Borén, Jan

AU - Fazio, Sergio

AU - Horton, Jay D.

AU - Masana, Luis

AU - Nicholls, Stephen J.

AU - Nordestgaard, Børge G.

AU - Van De Sluis, Bart

AU - Taskinen, Marja Riitta

AU - Tokgözoǧlu, Lale

AU - Landmesser, Ulf

AU - Laufs, Ulrich

AU - Wiklund, Olov

AU - Stock, Jane K.

AU - Chapman, M. John

AU - Catapano, Alberico L.

PY - 2017/8/21

Y1 - 2017/8/21

N2 - Aims To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD). Methods and results We assessed whether the association between LDL and ASCVD fulfils the criteria for causality by evaluating the totality of evidence from genetic studies, prospective epidemiologic cohort studies, Mendelian randomization studies, and randomized trials of LDL-lowering therapies. In clinical studies, plasma LDL burden is usually estimated by determination of plasma LDL cholesterol level (LDL-C). Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD, whereas rare variants leading to lower LDL-C are associated with a correspondingly lower risk of ASCVD. Separate meta-analyses of over 200 prospective cohort studies, Mendelian randomization studies, and randomized trials including more than 2 million participants with over 20 million person-years of follow-up and over 150 000 cardiovascular events demonstrate a remarkably consistent dose-dependent log-linear association between the absolute magnitude of exposure of the vasculature to LDL-C and the risk of ASCVD; and this effect appears to increase with increasing duration of exposure to LDL-C. Both the naturally randomized genetic studies and the randomized intervention trials consistently demonstrate that any mechanism of lowering plasma LDL particle concentration should reduce the risk of ASCVD events proportional to the absolute reduction in LDL-C and the cumulative duration of exposure to lower LDL-C, provided that the achieved reduction in LDL-C is concordant with the reduction in LDL particle number and that there are no competing deleterious off-target effects. Conclusion Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.

AB - Aims To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD). Methods and results We assessed whether the association between LDL and ASCVD fulfils the criteria for causality by evaluating the totality of evidence from genetic studies, prospective epidemiologic cohort studies, Mendelian randomization studies, and randomized trials of LDL-lowering therapies. In clinical studies, plasma LDL burden is usually estimated by determination of plasma LDL cholesterol level (LDL-C). Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD, whereas rare variants leading to lower LDL-C are associated with a correspondingly lower risk of ASCVD. Separate meta-analyses of over 200 prospective cohort studies, Mendelian randomization studies, and randomized trials including more than 2 million participants with over 20 million person-years of follow-up and over 150 000 cardiovascular events demonstrate a remarkably consistent dose-dependent log-linear association between the absolute magnitude of exposure of the vasculature to LDL-C and the risk of ASCVD; and this effect appears to increase with increasing duration of exposure to LDL-C. Both the naturally randomized genetic studies and the randomized intervention trials consistently demonstrate that any mechanism of lowering plasma LDL particle concentration should reduce the risk of ASCVD events proportional to the absolute reduction in LDL-C and the cumulative duration of exposure to lower LDL-C, provided that the achieved reduction in LDL-C is concordant with the reduction in LDL particle number and that there are no competing deleterious off-target effects. Conclusion Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.

KW - Atherosclerosis

KW - Cardiovascular disease

KW - Causality

KW - Clinical trials

KW - Ezetimibe

KW - Low-density lipoprotein

KW - Mendelian randomization

KW - PCSK9

KW - Recommendations

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=85027715986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027715986&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehx144

DO - 10.1093/eurheartj/ehx144

M3 - Article

VL - 38

SP - 2459

EP - 2472

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 32

ER -